Compare Moderna, Inc. (MRNA) vs Rockwell Automation (ROK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Rockwell Automation — how do they compare? Moderna, Inc. trades at $136.93 (market cap $54.14B), while Rockwell Automation trades at $427.73 (market cap $47.32B). The key difference: Moderna, Inc. and Rockwell Automation are close in size by market cap, and Rockwell Automation pays a 1.3% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| MRNA | ROK | |
|---|---|---|
Market Cap | $54.14B | $47.32B |
Sector | Health | Industrials |
52-Week High | $174.38 | $495.08 |
52-Week Low | $22.36 | $333.75 |
Enterprise Value | $50.29B | $50.45B |
Dividend Yield | — | 1.3% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $140.33, down 3.59% on the day, amid mixed signals. The stock has seen volatility, with a 143% surge over the past month driven by positive cancer vaccine trial results (Fox Business, 2026-09-06), but faces headwinds from declining revenue and persistent net losses. Technical analysis shows a bullish overall signal, with support at $138 and resistance at $145, while fundamentals reveal a challenging profit margin of -142.58% for 2026.
The outlook hinges on pipeline successes, particularly in oncology, but high valuation ratios and competitive pressures pose risks. Analyst consensus is cautious, with a $90.08 price target, reflecting skepticism despite recent clinical milestones. Investors should weigh innovation potential against financial sustainability and market sentiment shifts.
Rockwell Automation (ROK) trades at $429.13, down 1.08% on the day, with a bearish technical signal and mixed sentiment. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $3.49 exceeding expectations, but faces declining profit margins from 14.1% in 2023 to 10.41% in 2025. Analyst consensus is a Buy with a $514 price target, though technical indicators show resistance near $434 and support at $427.
The stock offers upside based on analyst targets and robust cash flow, but risks include margin pressure, high valuation multiples, and macroeconomic sensitivity. Institutional interest remains positive with recent investments, but investors should weigh the bearish technical trend against fundamental strengths in industrial automation demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Rockwell Automation
Rockwell Automation is a pure-play automation competitor that is the successor entity to Rockwell International, which spun off its former Rockwell Collins avionics segment in 2001. As of fiscal 2021, the firm operates through three segments--intelligent devices, software and control, and lifecycle services. Intelligent devices contains its drives, sensors, and industrial components, software and control contains its information and network and security software, while lifecycle services contains its consulting and maintenance services as well as its Sensia JV with Schlumberger.
Read more on ROK →
